Polarityte, Inc. PTE
We take great care to ensure that the data presented and summarized in this overview for POLARITYTE, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in PTE
Top Purchases
Top Sells
About PTE
PolarityTE, Inc., a clinical stage biotechnology company, develops and commercializes a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences in the United States. The company operates in two segments, Regenerative Medicine Products and Contract Services. It offers SkinTE, a tissue product used to repair, reconstruction, replacement, and supplementation of skin in patients for the treatment of acute or chronic wounds, burns, surgical reconstruction events, scar revision, or removal of dysfunctional skin grafts, as well as contract research services. The company also develops SkinTE Cryo allows multiple deployments from one original harvest through a cryopreservation process; SkinTE point-of-care device to permit the processing and deployment of SkinTE immediately following the initial harvest at the point-of-car; PTE 11000, an allogenic, biologically active dressing for use in wound care and aesthetics to accelerate healing of skin; and other tissue regeneration products. PolarityTE, Inc. is headquartered in Salt Lake City, Utah.
Insider Transactions at PTE
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 26
2023
|
Jeffrey Hansen Dyer Director |
BUY
Grant, award, or other acquisition
|
Direct |
42,986
+49.23%
|
$0
$0.79 P/Share
|
|
Jan 12
2023
|
Chris Nolet Director |
SELL
Exercise of conversion of derivative security
|
Direct |
36,497
-71.7%
|
-
|
|
Oct 01
2022
|
David B Seaburg Director |
BUY
Grant, award, or other acquisition
|
Direct |
50,900
+31.11%
|
-
|
|
Oct 01
2022
|
Chris Nolet Director |
BUY
Grant, award, or other acquisition
|
Direct |
50,900
+50.0%
|
-
|
|
Oct 01
2022
|
Peter A Cohen Director |
BUY
Grant, award, or other acquisition
|
Direct |
50,900
+46.68%
|
$0
$0.87 P/Share
|
|
Oct 01
2022
|
Willie C. Bogan Director |
BUY
Grant, award, or other acquisition
|
Direct |
50,900
+48.62%
|
-
|
|
Aug 17
2022
|
Peter A Cohen Director |
SELL
Open market or private sale
|
Direct |
8,555
-54.15%
|
$8,555
$1.28 P/Share
|
|
Aug 16
2022
|
Peter A Cohen Director |
SELL
Open market or private sale
|
Direct |
15,106
-1.96%
|
$15,106
$1.33 P/Share
|
|
Jul 18
2022
|
Jacob Alexander Patterson Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
142
-0.91%
|
$142
$1.47 P/Share
|
|
Jul 18
2022
|
Cameron J. Hoyler Gen. Counsel & Exec. VP |
SELL
Payment of exercise price or tax liability
|
Direct |
521
-1.41%
|
$521
$1.47 P/Share
|
|
Jul 18
2022
|
Richard Hague Chf. Exec. Off. & Pres. |
SELL
Payment of exercise price or tax liability
|
Direct |
474
-1.02%
|
$474
$1.47 P/Share
|
|
Jun 23
2022
|
Jacob Alexander Patterson Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
758
-4.63%
|
$758
$1.58 P/Share
|
|
Jun 23
2022
|
Cameron J. Hoyler Gen. Counsel & Exec. VP |
SELL
Payment of exercise price or tax liability
|
Direct |
1,269
-3.32%
|
$1,269
$1.58 P/Share
|
|
Jun 23
2022
|
Richard Hague Chf. Exec. Off. & Pres. |
SELL
Payment of exercise price or tax liability
|
Direct |
1,218
-2.57%
|
$1,218
$1.58 P/Share
|
|
May 02
2022
|
Cameron J. Hoyler Gen. Counsel & Exec. VP |
SELL
Payment of exercise price or tax liability
|
Direct |
20,747
-2.13%
|
$0
$0.18 P/Share
|
|
May 02
2022
|
Cameron J. Hoyler Gen. Counsel & Exec. VP |
BUY
Grant, award, or other acquisition
|
Direct |
60,000
+3.02%
|
-
|
|
May 02
2022
|
David B Seaburg Director |
BUY
Grant, award, or other acquisition
|
Direct |
80,000
+2.55%
|
-
|
|
May 02
2022
|
Richard Hague Chf. Exec. Off. & Pres. |
SELL
Payment of exercise price or tax liability
|
Direct |
19,479
-1.61%
|
$0
$0.18 P/Share
|
|
May 02
2022
|
Richard Hague Chf. Exec. Off. & Pres. |
BUY
Grant, award, or other acquisition
|
Direct |
80,000
+3.25%
|
-
|
|
May 02
2022
|
Jacob Alexander Patterson Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
17,299
-4.05%
|
$0
$0.18 P/Share
|